Tags : THOR-707

Sanofi Entered into an Agreement with Merck to Conduct a

Shots: Sanofi will sponsor the clinical trials while MSD will provide KEYTRUDA. Additionally, Sanofi is separately evaluating the activity of THOR-707 in combination with other anti-PD-1 antibodies, including Libtayo (cemiplimab-rwlc) and with anti-EGFR and anti-CD38 antibodies for various types of cancer tumors In preclinical studies, THOR-707 demonstrated the ability to induce the expansion of CD8+T-cells […]Read More

Sanofi to Acquire Synthorx for $2.5B

Shots: Sanofi to acquire Synthrox in all-cash transactions at $68/share, making a total deal value $2.5B with a premium of 172% to Synthorx’s closing price on December 6, 2019. The transaction is expected to be completed in Q1’20 The focus of the acquisition is to foster Sanofi’s immuno-oncology (IO) pipeline with the addition of Synthorx’s […]Read More